CONMED Corporation (CNMD) — ESG & Values Scores

Environment story

CONMED demonstrates moderate environmental performance with significant gaps in disclosure and strategic clarity. The company faces material exposure to EtO sterilization regulatory risk (31% of product revenues), which has prompted some facility closures in the U.S. No publicly disclosed Scope 1, 2, or 3 emissions data, carbon targets, or net-zero commitments appear in the 10-K filing. The company acknowledges climate change risk to operations (hurricanes, supply chain disruptions) but provides no emissions reduction strategy, renewable energy targets, or decarbonization initiatives. The 2025 10-K mentions engagement of consultants for manufacturing optimization and supply-chain reviews, but these appear cost-driven rather than environment-driven. Absence of third-party sustainability reporting or GRI/SASB disclosure limits transparency. The company's recognition of ESG regulatory evolution is reactive rather than proactive.

Criticisms on file

EtO Sterilization Facility Closures and Regulatory Risk
Source: CNMD 10-K 2025, Item 1A Risk Factors: 'some EtO sterilization facilities have closed, or are threatened with closure, either temporarily or permanently, in connection with government enforcement actions or enhanced regulations prompted by environmental concerns.'
No Disclosed Net-Zero or Science-Based Emissions Targets
Source: CNMD 10-K 2025: No mention of net-zero commitments, Scope 1/2/3 emissions, renewable energy percentage, or climate targets in the entire filing.
Supply Chain Disruption from Climate Events
Source: CNMD 10-K 2025, Item 1A Risk Factors: 'the path of Hurricane Milton temporarily impacted our manufacturing facility in Largo, Florida.'

Disclosed initiatives

EtO Sterilization Risk Mitigation

Company acknowledges regulatory pressure on EtO sterilization facilities (31% of revenues) and notes securing alternative third-party sterilizers; however, no transition timeline or alternative sterilization capacity investments disclosed.

Defensive measure; does not represent proactive decarbonization.
Manufacturing and Supply Chain Consultation (2025)

Engaged external consultants to evaluate and propose improvements to manufacturing operations and supply chain, incurring $12.5M in costs; discontinued certain product lines and wrote off $22.2M in inventory, equipment, tooling, and patents.

Cost-optimization driven; no explicit environmental benefit stated.
Climate Change Risk Acknowledgment

10-K Risk Factors section identifies shifts in weather patterns, frequency of hurricanes, floods, and extreme temperatures as potential business and supply chain risks; acknowledges increased costs from natural disasters.

Risk identification only; no mitigation strategy disclosed.

Social story

CONMED shows moderate social performance with significant disclosure gaps. CEO-to-worker pay ratio, leadership diversity metrics, and employee turnover are not disclosed in the 10-K. The company emphasizes talent attraction and retention as critical to success and notes competition for qualified personnel is intense in medical device manufacturing. No evidence of union suppression or major labor disputes in the past 24 months. The company operates a compliance program addressing false claims and anti-bribery laws and reported a voluntary DOJ disclosure regarding royalty payments to surgeon design-team members, which the DOJ closed without prosecution in September 2025. Supply-chain human-rights audit practices, labor standards audits, or conflict-minerals policies are not mentioned. Diversity and inclusion programs, if any exist, are not disclosed. The company maintains a frozen defined-benefit pension plan (2009) covering U.S. employees and acknowledges employee retention challenges but provides no formal diversity or living-wage commitments.

Criticisms on file

Royalty Payment Disclosure to DOJ (Surgeon Design Teams)
Source: CNMD 10-K 2025, Item 1A Risk Factors: 'we voluntarily informed the U.S. Department of Justice ('DOJ') of potential issues with certain royalty payments related to surgeons involved in design teams... On September 5, 2025, the DOJ informed the Company that it was declining to prosecute the Company, civilly or criminally, for any conduct related to the voluntary disclosure.'
No Disclosed Diversity or Pay Equity Metrics
Source: CNMD 10-K 2025: Filing contains no workforce diversity breakdown, gender/racial pay gap reporting, CEO-to-median-worker pay ratio, or EEO-1 disclosure.
Labor Supply Chain Audit and Human-Rights Standards Not Disclosed
Source: CNMD 10-K 2025: No mention of supply-chain labor audits, conflict minerals policies, modern slavery statements, living-wage commitments, or human-rights due diligence.

Disclosed initiatives

Corporate Compliance Program

Company implements compliance policies, training, auditing, and monitoring to address federal and state healthcare fraud and abuse laws, anti-bribery, anti-corruption, FCPA, and False Claims Act requirements.

Regulatory risk mitigation; supports ethical operations but does not directly address worker welfare or human rights.
Voluntary DOJ Disclosure on Surgeon Royalty Payments

Company voluntarily informed the U.S. Department of Justice of potential issues with certain royalty payments related to surgeons involved in design teams. DOJ declined to prosecute and closed investigation without further requirements on September 5, 2025.

Demonstrates proactive compliance and transparency; no material adverse impact to business.
Employee Attraction and Retention Focus

Company acknowledges that 'employees are our most important resource' and seeks to 'attract talented and diverse new employees and retain and motivate our existing employees.'

Recognition of talent importance; no specific metrics, programs, or diversity targets disclosed.
Frozen Defined-Benefit Pension Plan

Company sponsors a defined-benefit pension plan frozen in 2009 covering substantially all U.S.-based employees at the time of freeze; pension benefit obligation of $70.7M as of December 31, 2025.

Legacy benefit; frozen status means no new accruals for current employees.

Governance story

CONMED demonstrates moderate governance practices with structural anti-takeover protections and limited board independence disclosure. The 10-K does not disclose board independence percentage, number of independent directors, or board committee composition. The company operates under a single-class share structure (no dual-class voting rights disclosed), which is favorable. Anti-takeover provisions include: (i) board ability to issue preferred stock without shareholder approval; (ii) special meeting requirements (25% shareholder threshold); (iii) advance notice procedures for director nominations; (iv) Delaware Section 203 business combination restrictions; and (v) Court of Chancery of Delaware exclusive forum. These provisions are standard for Delaware corporations but limit shareholder activism. Lobbying spend is not disclosed in the 10-K. The company faces no active antitrust proceedings or material financial-fraud allegations; however, it disclosed a voluntary DOJ investigation regarding surgeon royalty payments (closed without prosecution in September 2025). The company has not disclosed PAC contributions or political spending. Absence of third-party governance ratings (ISS, Glass Lewis) and limited transparency on executive compensation and board structure present governance weaknesses. The eighth amended and restated senior credit agreement (June 2025) contains standard restrictive covenants limiting acquisitions, divestitures, and dividend payments.

Criticisms on file

Limited Board Independence and Governance Transparency
Source: CNMD 10-K 2025: No disclosure of board independence percentage, number of independent directors, board committee structure, or executive compensation details beyond standard SEC filing requirements.
Anti-Takeover Provisions Limit Shareholder Rights
Source: CNMD 10-K 2025, Item 1A Risk Factors: Company maintains multiple anti-takeover measures including board ability to issue preferred stock without shareholder approval, 25% shareholder threshold for special meetings, advance notice requirements, and Delaware Section 203 restrictions, which 'could limit the opportunity for our shareholders to receive a premium for their shares.'
No Disclosed Lobbying Expenditures or Political Spending
Source: CNMD 10-K 2025: Filing contains no disclosure of annual lobbying spending, PAC contributions, political donation policies, or engagement with trade associations on regulatory matters.
High Indebtedness and Refinancing Risk
Source: CNMD 10-K 2025, Liquidity and Capital Resources: '$840.0 million of debt outstanding, representing 44% of total capitalization'; $800M convertible notes due June 2027 with no certainty on refinancing; company states 'We expect to seek incremental financing to fund the maturity of the 2.250% Convertible Notes. There can be no assurance we will be able to obtain such financing on acceptable terms.'

Disclosed initiatives

Voluntary DOJ Disclosure and Cooperation

Company voluntarily informed DOJ of potential royalty-payment compliance issues; DOJ declined to prosecute and closed investigation without further requirements (September 2025).

Demonstrates proactive governance and risk management; supports ethical business practices.
Corporate Integrity and Compliance Framework

Company implements comprehensive compliance program addressing federal/state healthcare laws, anti-bribery, anti-corruption, FCPA, False Claims Act, and other regulatory requirements; ongoing training and auditing.

Reduces regulatory and litigation risk; supports ethical governance.
Restrictive Credit Agreement Covenants

Eighth amended and restated senior credit agreement (June 10, 2025) includes financial ratio maintenance, restrictions on dividends, acquisitions, divestitures, and indebtedness; 91-day minimum liquidity covenant for convertible note maturity.

Constrains operational and strategic flexibility; protects lender interests and financial stability.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of CONMED Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open CONMED Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)